Physician

Alan W Chiemprabha, M.D.

According to 2025 Medicare claims, Alan Chiemprabha, M.D. (NPI: 1356350227) practices gastroenterology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Cabarrus, NC. This provider's primary affiliated billing organization is CABARRUS GASTROENTEROLOGY ASSOCIATES, PLLC (NPI: 1780790592; TIN: 561335650) and primary practice location at 28025-2438. Chiemprabha is affiliated with the Carolinas HealthCare System ACO, LLC (ACO ID: A3675), participating under the MSSP model.

Chiemprabha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 310 traditional Medicare patients, billed 5,336 HCPCS/CPT codes, and received $150,274 in Medicare payments. The top billing code was 45385 (Removal of polyps or growths of large bowel using an endoscope with mechanical snare). Part D data shows 1,418 prescription claims across 404 beneficiaries totaling $1,701,265 in drug costs, led by Stelara (Ustekinumab). 2023 DME data shows 26 claims. Open Payments data shows 110 records totaling $2,266. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $110,269 and ending at $150,274. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $318,219 to $1,701,265. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	519	1,174	$110,269
2016	527	1,164	$131,758
2017	499	1,175	$95,062
2018	525	1,155	$96,429
2019	529	3,629	$160,831
2020	410	1,993	$107,765
2021	418	1,649	$110,068
2022	380	5,358	$147,922
2023	332	7,034	$175,985
2024	310	5,336	$150,274

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	300	1,311	$318,219
2016	262	1,279	$293,982
2017	279	1,180	$241,500
2018	271	1,102	$332,171
2019	276	1,127	$347,704
2020	280	1,215	$489,820
2021	337	1,466	$822,896
2022	335	1,358	$1,064,918
2023	332	1,203	$1,357,272
2024	404	1,418	$1,701,265

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	22	$4,210
2023	N/R	26	$5,379
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
45385	Removal of polyps or growths of large bowel using an endoscope with mechanical snare	63	64	$189
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	40	40	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	55	61	$87
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	65	66	$67
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	141	221	$62

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Stelara	Ustekinumab	19	1,010	$526,353
Gattex	Teduglutide	11	330	$509,790
Humira(Cf) Pen	Adalimumab	13	364	$209,200
Zenpep	Lipase/Protease/Amylase	21	979	$113,006
Linzess	Linaclotide	111	5,850	$103,136

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	110	$2,266	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan W. Chiemprabha, M.D.?

Tedicare shows public-source Medicare data for Alan W. Chiemprabha, M.D. (NPI 1356350227), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan W. Chiemprabha, M.D. have ACO affiliation data?

Alan W. Chiemprabha, M.D. is shown with ACO affiliation data for Carolinas HealthCare System ACO, LLC (MSSP, ACO ID A3675).

What billing organization is linked to Alan W. Chiemprabha, M.D.?

Alan W. Chiemprabha, M.D. is linked to CABARRUS GASTROENTEROLOGY ASSOCIATES, PLLC (billing NPI 1780790592) in the available physician profile data.

Does Alan W. Chiemprabha, M.D. have Open Payments data?

Alan W. Chiemprabha, M.D. has 110 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.